These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 32956600)

  • 1. Prevalence of Human Papillomavirus and Estimation of Human Papillomavirus Vaccine Effectiveness in Thimphu, Bhutan, in 2011-2012 and 2018 : A Cross-sectional Study.
    Baussano I; Tshomo U; Tenet V; Heideman DAM; Wangden T; Franceschi S; Clifford GM
    Ann Intern Med; 2020 Dec; 173(11):888-894. PubMed ID: 32956600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human papillomavirus vaccine effect against human papillomavirus infection in Rwanda: evidence from repeated cross-sectional cervical-cell-based surveys.
    Sayinzoga F; Tenet V; Heideman DAM; Sibomana H; Umulisa MC; Franceschi S; Hakizimana JD; Clifford GM; Baussano I
    Lancet Glob Health; 2023 Jul; 11(7):e1096-e1104. PubMed ID: 37207683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urine testing to monitor the impact of HPV vaccination in Bhutan and Rwanda.
    Franceschi S; Chantal Umulisa M; Tshomo U; Gheit T; Baussano I; Tenet V; Tshokey T; Gatera M; Ngabo F; Van Damme P; Snijders PJ; Tommasino M; Vorsters A; Clifford GM
    Int J Cancer; 2016 Aug; 139(3):518-26. PubMed ID: 26991686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Human Papillomavirus Vaccination, Rwanda and Bhutan.
    Baussano I; Sayinzoga F; Tshomo U; Tenet V; Vorsters A; Heideman DAM; Gheit T; Tommasino M; Umulisa MC; Franceschi S; Clifford GM
    Emerg Infect Dis; 2021 Jan; 27(1):1-9. PubMed ID: 33350922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program.
    Garland SM; Cornall AM; Brotherton JML; Wark JD; Malloy MJ; Tabrizi SN;
    Vaccine; 2018 May; 36(23):3221-3230. PubMed ID: 29724506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low prevalence of vaccine-type HPV infections in young women following the implementation of a school-based and catch-up vaccination in Quebec, Canada.
    Goggin P; Sauvageau C; Gilca V; Defay F; Lambert G; Mathieu-C S; Guenoun J; Comète E; Coutlée F
    Hum Vaccin Immunother; 2018 Jan; 14(1):118-123. PubMed ID: 29049007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study.
    Tabrizi SN; Brotherton JM; Kaldor JM; Skinner SR; Liu B; Bateson D; McNamee K; Garefalakis M; Phillips S; Cummins E; Malloy M; Garland SM
    Lancet Infect Dis; 2014 Oct; 14(10):958-66. PubMed ID: 25107680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human papillomavirus infection in Bhutan at the moment of implementation of a national HPV vaccination programme.
    Tshomo U; Franceschi S; Dorji D; Baussano I; Tenet V; Snijders PJ; Meijer CJ; Bleeker MC; Gheit T; Tommasino M; Clifford GM
    BMC Infect Dis; 2014 Jul; 14():408. PubMed ID: 25047665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy.
    Carozzi F; Puliti D; Ocello C; Anastasio PS; Moliterni EA; Perinetti E; Serradell L; Burroni E; Confortini M; Mantellini P; Zappa M; Dominiak-Felden G
    BMC Infect Dis; 2018 Jan; 18(1):38. PubMed ID: 29334901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human papillomavirus prevalence and vaccine effectiveness in young women in Germany, 2017/2018: results from a nationwide study.
    Loenenbach A; Schönfeld V; Takla A; Wiese-Posselt M; Marquis A; Thies S; Sand M; Kaufmann AM; Wichmann O; Harder T
    Front Public Health; 2023; 11():1204101. PubMed ID: 37719724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Introduction of a National HPV vaccination program into Bhutan.
    Dorji T; Tshomo U; Phuntsho S; Tamang TD; Tshokey T; Baussano I; Franceschi S; Clifford G
    Vaccine; 2015 Jul; 33(31):3726-30. PubMed ID: 26057136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction in Vaccine HPV Type Infections in a Young Women Group (18-25 Years) Five Years after HPV Vaccine Introduction in Colombia.
    Combita AL; Reyes V; Puerto D; Murillo R; Sánchez R; Nuñez M; Hernandez-Suarez GA; Wiesner C
    Cancer Prev Res (Phila); 2022 Jan; 15(1):55-66. PubMed ID: 34610993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study.
    Kavanagh K; Pollock KG; Cuschieri K; Palmer T; Cameron RL; Watt C; Bhatia R; Moore C; Cubie H; Cruickshank M; Robertson C
    Lancet Infect Dis; 2017 Dec; 17(12):1293-1302. PubMed ID: 28965955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and Types of Human Papillomavirus Infections in Adolescent Girls and Young Women Immunized With the Human Papillomavirus Vaccine.
    Schlecht NF; Diaz A; Nucci-Sack A; Shyhalla K; Shankar V; Guillot M; Hollman D; Strickler HD; Burk RD
    JAMA Netw Open; 2021 Aug; 4(8):e2121893. PubMed ID: 34424304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study.
    Chow EP; Danielewski JA; Fehler G; Tabrizi SN; Law MG; Bradshaw CS; Garland SM; Chen MY; Fairley CK
    Lancet Infect Dis; 2015 Nov; 15(11):1314-23. PubMed ID: 26201300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Impact of Girls-Only Human Papillomavirus 16/18 Vaccination in The Netherlands: Cross-Protective and Second-Order Herd Effects.
    Hoes J; Woestenberg PJ; Bogaards JA; King AJ; de Melker HE; Berkhof J; Hoebe CJPA; van der Sande MAB; van Benthem BHB;
    Clin Infect Dis; 2021 Mar; 72(5):e103-e111. PubMed ID: 33249475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study.
    Chow EPF; Machalek DA; Tabrizi SN; Danielewski JA; Fehler G; Bradshaw CS; Garland SM; Chen MY; Fairley CK
    Lancet Infect Dis; 2017 Jan; 17(1):68-77. PubMed ID: 27282422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in genital Human Papillomavirus (HPV) prevalence among urban females a decade after the Malaysian HPV vaccination program.
    Khoo SP; Muhammad Ridzuan Tan NA; Rajasuriar R; Nasir NH; Gravitt P; Ng CW; Woo YL
    PLoS One; 2022; 17(12):e0278477. PubMed ID: 36538522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bivalent Vaccine Effectiveness Against Type-Specific HPV Positivity: Evidence for Cross-Protection Against Oncogenic Types Among Dutch STI Clinic Visitors.
    Woestenberg PJ; King AJ; van Benthem BHB; Donken R; Leussink S; van der Klis FRM; de Melker HE; van der Sande MAB; Hoebe CJPA; Bogaards JA;
    J Infect Dis; 2018 Jan; 217(2):213-222. PubMed ID: 29140439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human Papillomavirus (HPV) Vaccine Effectiveness and Potential Herd Immunity for Reducing Oncogenic Oropharyngeal HPV-16 Prevalence in the United Kingdom: A Cross-sectional Study.
    Mehanna H; Bryant TS; Babrah J; Louie K; Bryant JL; Spruce RJ; Batis N; Olaleye O; Jones J; Struijk L; Molijn A; Vorsters A; Rosillon D; Taylor S; D'Souza G
    Clin Infect Dis; 2019 Sep; 69(8):1296-1302. PubMed ID: 30590469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.